464results about How to "Good anti-inflammatory activity" patented technology

A method and medicament for anticoagulating a patient with a sulfated polysaccharide mixture that demonstrates enhanced anti-inflammatory activity compared to anticoagulation with unfractionated heparin comprising various combinations of fully anticoagulant unfractionated heparin with 2-O desulfated heparin demonstrating reduced anticoagulant activity but enhanced anti-inflammatory actions. The medicament preferably is administered intravenously, by aerosolization or orally. Preferably, the 2-O desulfated heparin medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, normal saline and distilled water. Additionally provided is a method of synthesizing 2-O desulfated heparin in commercially practical quantities for the formulation of an anticoagulant 2-O desulfated heparin and heparin mixture.

There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery.

Variants (mutants) of recombinant activated protein C (APC) or recombinant protein C (prodrug, capable of being converted to APC) that have substantial reductions in anticoagulant activity but that retain normal levels of anti-apoptotic activity are provided. Two examples of such recombinant APC mutants are KKK191-193AAA-APC and RR229 / 230M-APC. APC variants and prodrugs of the invention have the desirable property of being cytoprotective (anti-apoptotic effects), while having significantly reduced risk of bleeding. The invention also provides a method of using the APC variants or prodrugs of the invention to treat subjects who will benefit from APC's cytoprotective activities that are independent of APC's anticoagulant activity. These subjects include patients at risk of damage to blood vessels or tissue in various organs caused, at least in part, by apoptosis. At risk patients include, for example, those suffering (severe) sepsis, ischemia / reperfusion injury, ischemic stroke, acute myocardial infarction, acute or chronic neurodegenerative diseases, or those undergoing organ transplantation or chemotherapy, among other conditions. Methods of screening for variants of recombinant protein C or APC that are useful in accordance with the invention are also provided.

The invention discloses an application of a compound to preparation of medicines for treating viral pneumonia, and relates to the technical field of drugs. The technical problem that novel antiviral drugs are deficient in the prior art, can be solved. The compound comprises a purine compound adopting the structure as shown in the formula 1, and / or an anthraquinone derivative adopting the structureas shown in the formula 2. The purine compound adopting the structure as shown in the formula 1, and / or the anthraquinone derivative adopting the structure as shown in the formula 2 both can show predominant effect for resisting viral pneumonia when being separately used or used jointly. Drugs for treating viral pneumonia, are prepared by the compound provided by the invention are more notable inactivity compared with clinical frontline drugs, and are better than drugs of ribavirin, oseltamivir and the like.

Amide derivatives represented by the formula (I):wherein:A is a cycloalkyl group, an aryl group or a heteroaryl group; X is a nitrogen atom or CR17; Y is —NRa—, —(CRbRb′)m-, and the like; m is 0 to 4; and R1 to R17 may be the same or different and each is a hydrogen atom, a halogen atom, a cyano group, a nitro group, a carboxyl group, a formyl group, a hydroxyl group, an ammonium group, an alkyl group optionally having one or more substituents, ZR18 and the like, Z is —O—, —S(O)p-, —S(O)pO—, —NH—, —NR19-, and the like; or R1 and R2 may in combination form a ring, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof may be applied to pharmaceutical use such as anti-inflammatory and analgesic action and the like.

The invention discloses a quinoid chalcone compound with a methyl group at an A ring, and a preparation method and anti-inflammatory activity thereof. The compound has a structure as shown in a general formula (I) which is described in the specification. The preparation method comprises the following steps: (1) synthesizing 2-hydroxy-4,6-dimethoxyacetophenone; (2) synthesizing 2'-hydroxy-4',6'-dimethoxychalcone derivative; (3) synthesizing 2',4',6'-trihydroxy chalcone derivative; and (4) synthesizing the quinoid chalcone compound with a methyl group at the A ring. The compound is simple to prepare and has obvious anti-inflammatory action.

The invention discloses a dammarane type triterpenoid saponin compound, a preparation method thereof and application thereof in preparation of anti-inflammatory drugs. The dammarane type triterpenoidsaponin compound is obtained by separation of cyclocarya paliurus leaves. The preparation method comprises steps of S1, extracting the cyclocarya paliurus leaves by using an alcohol solvent to obtainan extract, wherein the mass ratio of the cyclocarya paliurus leaves to the alcohol solvent is 1: (10-15); S2, separating the extract prepared in the step S1) sequentially by using silica gel column chromatography, MCI gel column choromatography, reversed-phase column choromatography, gel column choromatography and preparation type high performance liquid chromatography to obtain the compound. Thenew compound prepared by the method can suppress release of NO, TNF-alpha, PGE2 and IL-6 in LPS induced RAW264.7 cells, can reduce expression of iNOS, COX-2 and NF-KB / P65 protein, can take on good anti-inflammatory activity and can be used for developing related anti-inflammatory drugs.

The invention relates to hyperglycemia-hyperlipidemia-hypertension relieving health protection tea, and aims to solve the problems that the similar health care products are not obvious in hyperglycemia-hyperlipidemia-hypertension relieving effect and are scarce in raw materials. The hyperglycemia-hyperlipidemia-hypertension relieving health protection tea is prepared through the following steps: adding hawthorn fruits and wolfberry fruits into water, soaking for 10-20 minutes, heating and boiling for 5-10 minutes, and filtering to obtain filtrate; then adding coix seeds and licorice roots into the filtrate, soaking for 10-20 minutes, filtering and drying; finally, mixing the dried mixture with frosted folium mori and dicranostigma leptopodum, and grinding to obtain the hyperglycemia-hyperlipidemia-hypertension relieving health protection tea. The hyperglycemia-hyperlipidemia-hypertension relieving health protection tea is composed by taking traditional Chinese medicine theory as the bases; the components contained in the tea such as flavonoids, phenols, vitamins, carotenes, amino acids, mineral substances and organic acids can balance all nutritional ingredients for the human body; synthetic pharmacodynamic effects of all traditional Chinese medicines can be fully utilized to control or intervene hyperglycemia, hyperlipidemia and hypertension; therefore, the hyperglycemia-hyperlipidemia-hypertension relieving health protection tea has the efficacies of enhancing the body vigor, nursing the health, nourishing the vitality, recovering the langerhans gland function, relieving hyperglycemia, hyperlipidemia and hypertension, and diminishing the inflammation.

The present invention relates to the use of lignan compounds for treating or preventing an inflammatory disease. More particularly, it relates to a method for preventing or treating an inflammatory disease, comprising administering to a subject in need thereof an effective amount of macelignan represented by Chemical Formula I or a pharmaceutically acceptable salt thereof. The lignan compound has the effect of inhibiting inflammatory reactions by inhibiting the production or expression of inflammation mediators NO, iNOS, PGE2, COX-2 and TNF-α and by treating or preventing inflammatory disease in vivo. Accordingly, the lignan compound or a Myristica fragrans extract will be highly useful for the treatment or prevention of an inflammatory disease.

The present invention provides thienopyridine derivatives, which are useful as anti-inflammatory drugs, particularly as remedies for arthritis; processes for producing them, and pharmaceutical compositions containing them. The thienopyridine derivatives are represented by the formula (I):wherein G is a halogen atom, hydroxyl group, an optionally substituted amino group, etc.; alk is an optionally substituted lower alkylene group; X is O, S, -(CH2)q-, etc.; R is an optionally substituted amino group, etc.; ring B is an optionally substituted Y-containing 5- to 8-membered ring whose ring constituent atoms contain no nitrogen atom; Y is O, S, a group of(wherein Ra, Rb and Rc are the same or different and, each is H, a halogen atom, an optionally substituted hydrocarbon group, etc.), etc.; and ring A may be substituted.